Pharmaceutical Research

, Volume 31, Issue 11, pp 3095–3105 | Cite as

Aerosolized Montelukast Polymeric Particles—An Alternative to Oral Montelukast–Alleviate Symptoms of Asthma in a Rodent Model

Research Paper



Cysteinyl leukotrienes (CysLTs) propagate inflammatory reactions that result from allergen exposure in asthma. Montelukast, a CysLT type-1 receptor antagonist, disrupts mediator–receptor interactions and minimizes inflammatory response. In this study, we have evaluated anti-asthmatic efficacy of inhalable montelukast-loaded large porous particulate formulations in ovalbumin-induced rat airway inflammation model that mimics asthma.


The anti-inflammatory effects of a montelukast-loaded formulation were investigated in rats by measuring the total protein content, levels of injury markers and number of inflammatory cells in the bronchoalveolar lavage fluid (BALF). The histopathological studies assessed the morphological and structural changes that occur in asthmatic lungs. Animals were also challenged with methacholine to examine the airway hyper-reactivity.


Compared with healthy animals, asthmatic animals showed a 3.8- and 4.77-fold increase in the protein content and number of inflammatory cells in BALF, respectively. Intratracheal montelukast particles reduced the protein content by 3.3-fold and the number of inflammatory cells by 2.62-fold. Also, montelukast particles reduced the lactate dehydrogenase (LDH) and myeloperoxidase (MPO) levels by a 4.87- and 6.8-fold in BALF, respectively. Montelukast particles reduced the airway wall thickness by 2.5-fold compared with untreated asthmatic lungs. Further, particulate formulation protected the lungs against methacholine-induced bronchial provocation (p < 0.05).


Respirable large porous particles containing montelukast alleviated allergen-induced inflammatory response in an animal model and prevented histological changes associated with asthma. Thus montelukast-loaded large porous polylactic acid (PLA) particles could be an aerosolized delivery approach for administration of currently available oral montelukast.


anti-inflammatory asthma microparticles montelukast PLA 



Analysis of variance


Bronchoalveolar lavage fluid


Cysteinyl leukotriene type-1 receptor


Tidal midexpiratory flow


Horseradish peroxidase






Lactate dehydrogenase


Mass median aerodynamic diameter




Nicotinamide adenine dinucleotide






Poly (lactic acid)


Poly (lactide-co- glycolic acid)




3, 3′-5, 5′-Tetramethylbenzidine


  1. 1.
    Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype. Clin Exp Allergy. 2009;39(2):193–202.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma P. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469–78.PubMedCrossRefGoogle Scholar
  3. 3.
    Molimard M, Le Gros V, Robinson P, Bourdeix I. Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting. J Aerosol Med Pulm Drug Deliv. 2010;23(2):91–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Rosenberg K. Childhood asthma treatment can result in lower adult height: potential effect of inhaled glucocorticoids must be weighed against known benefits. Am J Nurs. 2012;112(12):14.CrossRefGoogle Scholar
  5. 5.
    Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367(10):904–12.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Singh SB, Weinberger MM, Zimmerman MB, Starner TD. Growth of preschool age children receiving daily inhaled corticosteroids. Allergy Asthma Proc. 2013;34(6):511–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Tintinger GR, Feldman C, Theron AJ, Anderson R. Montelukast: more than a cysteinyl leukotriene receptor antagonist? ScientificWorldJournal. 2010;10:2403–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Muraki M, Imbe S, Sato R, Ikeda Y, Yamagata S, Iwanaga T, et al. Inhaled montelukast inhibits cysteinyl-leukotriene-induced bronchoconstriction in ovalbumin-sensitized guinea-pigs: the potential as a new asthma medication. Int Immunopharmacol. 2009;9(11):1337–41.PubMedCrossRefGoogle Scholar
  9. 9.
    Philip G, Villaran C, Shah SR, Vandormael K, Smugar SS, Reiss TF. The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. J Asthma. 2011;48(5):495–502.PubMedCrossRefGoogle Scholar
  10. 10.
    Rawat A, Majumder QH, Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release. 2008;128(3):224–32.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Patel B, Gupta V, Ahsan F. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin. J Control Release. 2012;162(2):310–20.PubMedCrossRefGoogle Scholar
  12. 12.
    Gupta V, Rawat A, Ahsan F. Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension. J Pharm Sci. 2010;99(4):1774–89.PubMedGoogle Scholar
  13. 13.
    Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res. 1999;16(11):1735–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Ungaro F, De Rosa G, Miro A, Quaglia F, La Rotonda MI. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci. 2006;28(5):423–32.PubMedCrossRefGoogle Scholar
  15. 15.
    Moss OR. Simulants of lung interstitial fluid. Health Phys. 1979;36(3):447–8.PubMedGoogle Scholar
  16. 16.
    Onoue S, Matsui T, Kuriyama K, Ogawa K, Kojo Y, Mizumoto T, et al. Inhalable sustained-release formulation of long-acting vasoactive intestinal peptide derivative alleviates acute airway inflammation. Peptides. 2012;35(2):182–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Onoue S, Aoki Y, Matsui T, Kojo Y, Misaka S, Mizumoto T, et al. Formulation design and in vivo evaluation of dry powder inhalation system of new vasoactive intestinal peptide derivative ([R(15, 20, 21), L(17), A(24,25), des-N(28)]-VIP-GRR) in experimental asthma/COPD model rats. Int J Pharm. 2011;410(1–2):54–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Glaab T, Daser A, Braun A, Neuhaus-Steinmetz U, Fabel H, Alarie Y, et al. Tidal midexpiratory flow as a measure of airway hyperresponsiveness in allergic mice. Am J Physiol Lung Cell. 2001;280(3):L565–73.Google Scholar
  19. 19.
    Gupta V, Ahsan F. Influence of PEI as a core modifying agent on PLGA microspheres of PGE(1), a pulmonary selective vasodilator. Int J Pharm. 2011;413(1–2):51–62.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276(5320):1868–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Misaka S, Aoki Y, Karaki S, Kuwahara A, Mizumoto T, Onoue S, et al. Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: anti-inflammatory effect in experimental asthmatic rats. Peptides. 2010;31(1):72–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Misaka S, Sato H, Yamauchi Y, Onoue S, Yamada S. Novel dry powder formulation of ovalbumin for development of COPD-like animal model: Physicochemical characterization and biomarker profiling in rats. Eur J Pharm Sci. 2009;37(3–4):469–76.PubMedCrossRefGoogle Scholar
  23. 23.
    Glick Jr JH. Serum lactate dehydrogenase isoenzyme and total lactate dehydrogenase values in health and disease, and clinical evaluation of these tests by means of discriminant analysis. Am J Clin Pathol. 1969;52(3):320–8.PubMedGoogle Scholar
  24. 24.
    Drent M, Cobben NAM, Henderson RF, Wouters EFM, van Dieijen Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J. 1996;9(8):1736–42.PubMedCrossRefGoogle Scholar
  25. 25.
    Sener G, Sehirli O, Velioglu-Ogunc A, Cetinel S, Gedik N, Caner M, et al. Montelukast protects against renal ischemia/reperfusion injury in rats. Pharmacol Res. 2006;54(1):65–71.PubMedCrossRefGoogle Scholar
  26. 26.
    Ahmed AAE. Protective effect of montelukast on paraquat-induced lung toxicity in rats. Biosci Trends. 2009;3(2):63–72.PubMedGoogle Scholar
  27. 27.
    Ihaku D, Cameron L, Suzuki M, Molet S, Martin J, Hamid Q. Montelukast, a leukotriene receptor antagonist, inhibits the late airway response to allergen, airway eosinophilia, and IL-5-expressing cells in Brown Norway rats. J Allergy Clin Immunol. 1999;104(6):1147–54.PubMedCrossRefGoogle Scholar
  28. 28.
    Minoguchi K, Kohno Y, Minoguchi H, Kihara N, Sano Y, Yasuhara H, et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest. 2002;121(3):732–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Kosciuch J, Krenke R, Gorska K, Zukowska M, Maskey-Warzechowska M, Chazan R. Relationship between airway wall thickness assessed by high-resolution computed tomography and lung function in patients with asthma and chronic obstructive pulmonary disease. J Physiol Pharmacol. 2009;60 Suppl 5:71–6.PubMedGoogle Scholar
  30. 30.
    Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care. 2001;164(10):S28–38.CrossRefGoogle Scholar
  31. 31.
    Henderson Jr WR, Chiang GK, Tien YT, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med. 2006;173(7):718–28.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Henderson Jr WR, Tang LO, Chu SJ, Tsao SM, Chiang GK, Jones F, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002;165(1):108–16.PubMedCrossRefGoogle Scholar
  33. 33.
    Ordonez CL, Khashayar R, Wong HH, Ferrando R, Wu R, Hyde DM, et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care. 2001;163(2):517–23.CrossRefGoogle Scholar
  34. 34.
    Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol. 2006;118(3):551–9. quiz 60-1.PubMedCrossRefGoogle Scholar
  35. 35.
    Cockcroft DW. Direct challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. 2010;138(2 Suppl):18S–24.PubMedCrossRefGoogle Scholar
  36. 36.
    Oh YJ, Lee J, Seo JY, Rhim T, Kim SH, Yoon HJ, et al. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J Control Release. 2011;150(1):56–62.PubMedCrossRefGoogle Scholar
  37. 37.
    Yildiz A, John E, Ozsoy Y, Araman A, Birchall JC, Broadley KJ, et al. Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against allergen-mediated airway hyper-reactivity and inflammation. J Control Release. 2012;162(2):456–63.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Brijeshkumar Patel
    • 1
  • Nilesh Gupta
    • 1
  • Fakhrul Ahsan
    • 1
  1. 1.Department of Pharmaceutical Sciences, School of PharmacyTexas Tech University Health Sciences CenterAmarilloUSA

Personalised recommendations